Based on the 4D Molecular Therapeutics Inc stock forecast from 3 analysts, the average analyst target price for 4D Molecular Therapeutics Inc is USD 14.25 over the next 12 months. 4D Molecular Therapeutics Inc’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of 4D Molecular Therapeutics Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, 4D Molecular Therapeutics Inc’s stock price was USD 2.76. 4D Molecular Therapeutics Inc’s stock price has changed by -15.85% over the past week, -32.19% over the past month and -89.75% over the last year.
No recent analyst target price found for 4D Molecular Therapeutics Inc
No recent average analyst rating found for 4D Molecular Therapeutics Inc
Company Overview 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherland and the United States. The company's lead product candidate, 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with a single, safe, and intravitreal injection; and 4D-710 for the treatment of cystic fibrosis through early-stage studies. It also develops 4D-175 for geographic atrophy in preclinical with open IND; 4D-725 for alpha-1 anti-trypsin deficiency lung disease in preclinical; and 4D-310 for Fabry disease, which is in Phase 1 clinical trials. The company has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; uniQure biopharma B.V; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California. Read Less
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherland and the United States. The company's lead pro...Read More
Frequently Asked Questions About 4D Molecular Therapeutics Inc (FDMT) Stock
Based on ratings from 3 analysts 4D Molecular Therapeutics Inc's stock is Under-perform. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, 2 sell and 1 hold ratings.
Unfortunately we do not have enough data on FDMT's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for FDMT is USD 14.25 over the next 12 months. The maximum analyst target price is USD 28 while the minimum anlayst target price is USD 6.
Unfortunately we do not have enough data on FDMT's stock to indicate if its overvalued.
The last closing price of FDMT's stock was USD 2.76.
The most recent market capitalization for FDMT is USD 0.17B.
Based on targets from 3 analysts, the average taret price for FDMT is projected at USD 14.25 over the next 12 months.
This means that FDMT's stock price may go up by +416.30% over the next 12 months.
We can't find any ETFs which contains 4D Molecular Therapeutics Inc's stock.
As per our most recent records 4D Molecular Therapeutics Inc has 0 Employees.
4D Molecular Therapeutics Inc's registered address is 5858 Horton Street, Emeryville, CA, United States, 94608.
You can get more information about it from 4D Molecular Therapeutics Inc's website at https://www.4dmoleculartherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About 4D Molecular Therapeutics Inc (FDMT) Stock
Based on ratings from 3 analysts 4D Molecular Therapeutics Inc's stock is Under-perform. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, 2 sell and 1 hold ratings.
Unfortunately we do not have enough data on FDMT's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for FDMT is USD 14.25 over the next 12 months. The maximum analyst target price is USD 28 while the minimum anlayst target price is USD 6.
Unfortunately we do not have enough data on FDMT's stock to indicate if its overvalued.
The last closing price of FDMT's stock was USD 2.76.
The most recent market capitalization for FDMT is USD 0.17B.
Based on targets from 3 analysts, the average taret price for FDMT is projected at USD 14.25 over the next 12 months.
This means that FDMT's stock price may go up by +416.30% over the next 12 months.
We can't find any ETFs which contains 4D Molecular Therapeutics Inc's stock.
As per our most recent records 4D Molecular Therapeutics Inc has 0 Employees.
4D Molecular Therapeutics Inc's registered address is 5858 Horton Street, Emeryville, CA, United States, 94608.
You can get more information about it from 4D Molecular Therapeutics Inc's website at https://www.4dmoleculartherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for FDMT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
